Cisplatin

erb-b2 receptor tyrosine kinase 2 ; Homo sapiens







149 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
101 19800108 Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer. 2009 Dec 1
102 19887555 Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. 2009 Nov 1
103 17885815 Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu. 2008 Jan 2
104 18448999 Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. 2008 May 2
105 18756958 [Influence of human epidermal growth factor receptor-2 siRNA on chemosensitivity to cisplatin of human ovarian carcinoma cells: an in vitro experiment]. 2008 Apr 1 11
106 18337622 Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. 2007 1
107 16549824 Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. 2006 Apr 20 1
108 16638299 [The effect of siRNA-Her2/neu on the drug sensitivity of Her2/neu-overexpressing lung adenocarcinoma cell line]. 2006 Jan 1
109 16681908 [Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2]. 2006 Mar 7 2
110 15703820 Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. 2005 Mar 1
111 15890569 Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. 2005 Jun 1 1
112 16372489 High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. 2005 Dec 2
113 14998864 Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression. 2004 Mar 1
114 15013588 Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. 2004 Apr 1
115 15585076 Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. 2004 Dec 1
116 14512646 Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan. 2003 2
117 11748447 The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review). 2002 Jan-Feb 2
118 11973639 Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. 2002 Apr 25 2
119 12036454 Enhanced anti-tumor effect of trastuzumab in combination with cisplatin. 2002 May 4
120 12070798 [Expression of c-erbB-2 and topoisomerase II alpha in relation to chemoresistance in ovarian cancer]. 2002 Mar 1
121 12108894 The current status of docetaxel for metastatic breast cancer. 2002 Jun 2
122 12174876 ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. 2002 Jul-Aug 3
123 12452011 [Synergistic cytotoxic effect of immunotoxin HEL-PE38KDEL and cis-platin against tumor cells]. 2002 Apr 1
124 11399867 Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. 2001 Jul-Aug 7
125 11774202 Targeting HER2: recent developments and future directions for breast cancer patients. 2001 Dec 1
126 11899413 Platinum compounds in the treatment of advanced breast cancer. 2001 Oct 2
127 10761709 Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. 2000 Feb 1
128 10781891 Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. 2000 Apr 3 1
129 10327070 Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. 1999 Apr 1 2
130 10397267 Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. 1999 Jul 1 1
131 10482199 Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. 1999 Aug 1
132 10631474 Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. 1999 Nov 1
133 10697535 Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells. 1999 Nov-Dec 11
134 9563896 Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2. 1998 Apr 1
135 9662255 Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. 1998 Jul 1
136 9704716 Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. 1998 Aug 4
137 9811454 Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. 1998 Oct 29 5
138 9845103 Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. 1998 Nov 1 2
139 9872333 Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells. 1998 Dec 17 1
140 9150389 Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway. 1997 Apr 17 4
141 9374379 Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. 1997 2
142 9493954 The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. 1997 1
143 8637714 Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. 1996 Feb 1 2
144 8640763 Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. 1996 Mar 1 1
145 9816272 Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. 1996 Jul 1
146 7896881 p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. 1995 Mar 2
147 7911565 Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. 1994 Jul 6
148 7913407 p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. 1994 Jul 15 1
149 1678683 A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. 1991 Sep 1 1